Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Vincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, Daniel Wetterskog, Samanta Salvi, Giorgia Gurioli, Emanuela Scarpi, Elena Castro, Mercedes Marin-Aguilera, Cristian Lolli, Giuseppe Schepisi, Antonio Maugeri, Anna Wingate, Alberto Farolfi, Valentina Casadio, Ana Medina, Javier Puente, Mª José Méndez Vidal, Rafael Morales-Barrera, Jose C. Villa-GuzmánSusana Hernando, Alejo Rodriguez-Vida, Aránzazu González-del-Alba, Begoña Mellado, Enrique Gonzalez-Billalabeitia, David Olmos, Gerhardt Attard, Ugo De Giorgi

Research output: Contribution to journalArticle

Abstract

Analysis of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line therapy showed that plasma androgen receptor (AR)-normal status favored treatment with abiraterone or enzalutamide, whilst docetaxel benefit was unrelated to plasma AR. AR testing in plasma may have clinical utility for treatment selection in mCRPC.

Original languageEnglish
Pages (from-to)368-373
Number of pages6
JournalEuropean Urology
Volume75
Issue number3
DOIs
Publication statusPublished - Mar 2019

Keywords

  • Androgen receptor
  • Androgen receptor–directed therapies
  • Biomarker
  • Castration-resistant prostate cancer
  • Docetaxel
  • Plasma DNA

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer'. Together they form a unique fingerprint.

  • Cite this

    Conteduca, V., Jayaram, A., Romero-Laorden, N., Wetterskog, D., Salvi, S., Gurioli, G., Scarpi, E., Castro, E., Marin-Aguilera, M., Lolli, C., Schepisi, G., Maugeri, A., Wingate, A., Farolfi, A., Casadio, V., Medina, A., Puente, J., Vidal, M. J. M., Morales-Barrera, R., ... De Giorgi, U. (2019). Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. European Urology, 75(3), 368-373. https://doi.org/10.1016/j.eururo.2018.09.049